T Cells Can Target Receptor Found on Many Ovarian Tumors

Article

A study found that follicle-stimulating hormone receptors are expressed in many ovarian tumors, and not in normal ovarian tissue, thus representing a promising therapeutic target.

A laboratory study found that follicle-stimulating hormone receptors (FSHRs) are expressed in many ovarian tumors, and not in normal ovarian tissue, and thus represents a promising therapeutic target. Using human T cells targeted at those FSHRs increased survival in mice and could represent a novel approach to treating ovarian cancer.

Five-year survival rates for ovarian cancer patients have barely changed over the past 40 years. “Ovarian cancer is, however, an immunogenic tumor,” wrote study authors led by José R. Conejo-Garcia, MD, PhD, of the Wistar Institute in Philadelphia.

The study first involved testing for FSHR expression in various ovarian tumor cell lines, and then tested whether modified T cells could target that receptor. The results were published in Clinical Cancer Research.

In an initial analysis of 404 high-grade serous ovarian carcinomas (which represents about 70% of all epithelial ovarian cancers), 56.4% of the tumors expressed FSHR mRNA. It is not expressed in other healthy tissue including liver, contrary to some other recent research.

A further analysis of 28 stage III/IV serous carcinomas from the Wistar Institute’s tumor bank showed that 50% expressed FSHRs. Other histologic subtypes were even more likely to express FSHRs: it was found in 70% of endometrioid carcinomas, 67% of mucinous carcinomas, and was less prominent in clear cell carcinomas at 33%. FSHRs were not found in ovarian carcinosarcomas.

The researchers then used a modified version of chimeric antigen receptor T-cell technology to target the receptor. These T cells were used to treat mice with ovarian malignancies.

The T cells “induced rejection” of a patient-derived xenograft that expressed the highest FSHR levels, and also delayed the growth of a tumor with lower FSHR levels than is found in most primary ovarian malignancies. The researchers noted that the antitumor effects of the treatment do seem to depend on FSHR expression levels.

In another mouse experiment, only two intraperitoneal injections of the chimeric T cells were sufficient to significantly prolong survival of mice with an “aggressive” ovarian tumor. Importantly, no obvious adverse effects were seen, including no evidence of weight loss or signs of distress.

“Overall, our study demonstrates the effectiveness and safety of targeting chimeric receptors for T-cell activation using full-length hormones and unveils mechanisms of therapeutic activity that contribute to understanding the effects of adoptively transferred T cells in ongoing and future clinical trials,” the authors concluded. In a press release, they suggested that in the future this therapy could possibly be used after initial surgery and chemotherapy as a way to reduce the chances of recurrence.

Related Videos
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content